Telix 1H 2022 Financial Results and Company Update Investor Call
Telix advises that it will release financial results for the half-year ending 30 June 2022 on Thursday 18 August…
Read more
News & Views
Telix advises that it will release financial results for the half-year ending 30 June 2022 on Thursday 18 August…
Read more
Telix today reports on regulatory progress for the Company’s core prostate and kidney cancer imaging programs in the Asia Pacific (APAC) Operating Region, including progress in the major market of…
Read more
Telix and BAMF Health use Illuccix® for the first time with uEXPLORER® total-body PET scanner for prostate cancer…
Read more
Telix issues Appendix 4C quarterly cash flow statement and accompanying Activities Report for the quarter ended 30 June…
Read more
Telix Announces a Final Patient Dosed and Recruitment Completed into the Phase III Pivotal ZIRCON Study of TLX250-CDx for Kidney Cancer…
Read more
News,
Telix announces that Kevin Richardson will commence in the role of CEO, Telix Americas, on 11 July…
Read more
As a specialist in urology, Telix is delighted to invite you onboard the PSMA train. Our symposium, taking place during the EAU Congress 2022, will be an opportunity to ensure…
Read more
Telix is pleased to present a webcast of CEO and MD Dr. Christian Behrenbruch presenting at the Jefferies Global Healthcare Conference in New York City on Friday 10…
Read more
Telix is sponsoring a symposium and presenting the company’s prostate cancer imaging agent and clinical programs at #SNMMI22, being held in Vancouver, Canada from 11-14 June,…
Read more
Telix Chief Medical Officer, Dr. Colin Hayward, was hosted this week by Shane Storey, Senior Research Analyst at Wilsons Advisory and Stockbroking Limited, to discuss R&D insights across Telix’s imaging…
Read more